Opthea (ASX:OPT) completed the final week-52 patient visit in Coast, the first of two phase three trials evaluating a combination therapy candidate for wet age-related macular degeneration, an eye disease that can blur vision, according to a Tuesday Australian bourse filing.
The trial is investigating the superiority and safety of its drug candidate, sozinibercept, in combination with aflibercept, compared with the standard of care alone.
The company is also conducting a concurrent phase three trial assessing the combination of sozinibercept with ranibizumab.
Beyond week 52, patients will continue to be treated for an additional year to evaluate extended safety and tolerability up to a two-year period, the filing said.
Top-line results from the Coast trial are anticipated in the second quarter.
The company's shares were up almost 1% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.